Literature DB >> 11405298

Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity.

R Matsushita1, K Hattori, K Hayashi, H Iizasa, F Ichimura, E Nakashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11405298     DOI： 10.1023/a:1011048905732

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  13 in total

1.  Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line.

Authors:  M Stoeck; S Miescher; H R MacDonald; V Von Fliedner
Journal:  J Cell Physiol       Date:  1989-10       Impact factor: 6.384

Review 2.  Immune deficiency in SCID mice.

Authors:  S Nonoyama; H D Ochs
Journal:  Int Rev Immunol       Date:  1996       Impact factor: 5.311

3.  Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells.

Authors:  S Shimizu; Y Nishikawa; K Kuroda; S Takagi; K Kozaki; S Hyuga; S Saga; M Matsuyama
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

4.  Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats.

Authors:  P I Homem-de-Bittencourt Júnior; V Pontieri; R Curi; O U Lopes
Journal:  Braz J Med Biol Res       Date:  1989       Impact factor: 2.590

5.  Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor beta in rats bearing KDH-8 hepatoma cells.

Authors:  L Yuan; M Kobayashi; Y Kuramitsu; Y Li; K Matsushita; M Hosokawa
Journal:  Cancer Immunol Immunother       Date:  1997-10       Impact factor: 6.968

6.  Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice.

Authors:  M Tanaka; H Miyazaki; Y Takeda; S Takeo
Journal:  Cancer Lett       Date:  1993-08-16       Impact factor: 8.679

7.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.

Authors:  K Nakata; S Kashimoto; H Yoshida; T Oku; S Nakamura
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

9.  Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants.

Authors:  Y Tanaka; T Tanaka; H Ishitsuka
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

10.  Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour.

Authors:  S M Mahony; S A Beck; M J Tisdale
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.